Brendans primary responsibility is managing all aspects of the tax function. Toms primary responsibility is to support all aspects of trade and treasury operations. Senior executives interested in a position with one of our portfolio companies are also welcome to submit their resume and a description of their desired position. Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to joining RA, Kyle was a Partner at Breakthrough Energy Ventures (BEV), where he led investments and served on company boards that span the utilities, energy storage, chemicals, agriculture, automotive, recycling, and consumer products sectors. Adam Rosenberg is an Advisor for RA Capital Management. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Prior to this role, Alyssa mapped a number of competitive landscapes of drugs and medical devices for disease indications and capabilities. Maryann received her Bachelor of Science in English from Northeastern University. Robert Nicol is a Venture Partner at RA Ventures (RAVen), focusing on company creation. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio, leading hiring across all functions and building out systems to support that growth. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Alexs primary responsibility at RA Capital is to partner with the Investment Team to develop quantitative analyses to support investment decisions and inform portfolio management.
'All These Sons,' 'Peter Case: A Million Miles Away' Set 2023 Release Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. He holds a MS from Northeastern University and a BA from Hamilton College. Prior to RA, she served as Researcher and Collaborator at New Care, a startup focused on improving access to early childcare for lower income families. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. Astha holds a BA in Biochemistry and Molecular Biology (with a minor in Physics) from Clark University. View Profile. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. as a Staff Accountant. Prior to joining RA, Kathryn was SVP of Strategy at Energetic Insurance where she addressed regulatory-driven commercial lender limitations to enable financing for renewable energy and efficiency via financial insurance products. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Tom Thomas is an Associate with the TechAtlas division of RA Capital Management. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. James Schneider is the Deputy General Counsel at RA Capital Management. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. She earned an MBA with focus in entrepreneurship & strategic management from AB Freeman School of Business at Tulane University and her MD from Tulane School of Medicine. Fuad Naser is a Senior Associate with the TechAtlas division of RA Capital Management. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Her primary responsibilities are to assist with all finance operations related to the Firm. Peter Kolchinsky, RA Capital's founder and managing partner. Rez brings to RA over 20 years of experience working in the life-science industry. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Neil Buckley is an EIR at RA Capital. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. From 1990- 1997, he held investment, business development, R&D, and marketing positions at DuPont Ventures. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). Andrew is a Software Developer at RA Capital Management. Alex is an Associate with the TechAtlas division of RA Capital Management.
Peter Kolchinsky, Ph.D. - Forma Therapeutics Joe DeMaio is IT Operations Associate at RA Capital Management. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Michael Sherman is a Venture Partner at RA Ventures. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. According to Famous Birthdays, Peter was born on June 14, 1984, which makes him 38 years old, going on 39 in 2023. Her graduate research investigated novel epigenetic regulators in glioblastoma. His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Roivant, he . Parents Need to Know. He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Before joining Rubius, Mark spent a decade launching, building or advising a portfolio of early-stage venture backed life-sciences companies, including Visterra, Living proof, Kala Pharmaceuticals, and Homology Medicines. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Michael held leadership positions at Citigroup Hedge Fund Services in both Fund Accounting and Product Management before joining Centerbridge. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. He had to juggle the demands of raising a family while also trying to pay for his children's education. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. His graduate research investigated innate immune responses after intracerebral hemorrhage. Matthew Feresten is a Business Systems Analyst at RA Capital Management. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. Abhishek is a Data Analyst Associate at RA Capital Management. Ding Sun is a Senior Software Engineer at RA Capital Management. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania.
RA Capital | Team Prior to that, he was a Life Sciences Investment Associate at Brigham Capital. May 27, 2022 (This is a long piece; click here to read it in Bionic Reading format, which may for some increase reading speed and comprehension. Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. in Biomedical Anthropology from the University of Pennsylvania. Her primary responsibilities are to provide strategic administrative support and to assist the co founder in various external and internal projects She previously held Senior Executive Assistant roles at Genuity Science and Charles River Laboratories, and served as Director of Operations at Gloucester Graphics, Inc. Amber has a dual BA concentration in International Business & Modern Languages from Northeastern University and studied abroad at American University of Paris.
Peter Kolchinsky | RA Capital Management Profile - TipRanks.com Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Natalie brings to RAVen more than six years of Administrative experience. Milind attended the residential Executive Program at The Wharton School of Management. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Kate holds a BA in Molecular Biology and Biochemistry from Rutgers University, and a PhD in Biochemistry from MIT. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Peyman holds a dual B.S. 1 reply 0 retweets 13 likes Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Peter Kolchinsky Founder and CEO RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Prithviraj comes to RA from CVS Health, where he was Director of HealthHUB Product Technology Strategy and Enablement. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Neil was a founder or founding team member of six companies incubated within RA Ventures, including Lusaris Therapeutics, Eliem Therapeutics ($ELYM), Aerovate Therapeutics ($AVTE), Imbria Pharmaceuticals, and Athenen Therapeutics (acquired by Eliem). This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems. Cameron is a Senior Research Assistant at RA Capital Management. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Prior to MP, she was a Consultant at Clarion Healthcare. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Timothy is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. Kate previously served as Health Law Assistant at Mintz. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Receptionist and Facilities Administrator. Sophie received her doctorate in CAR T cell therapy from Kings College London, her pre-clinical medical degree from St Johns College, University of Oxford, and her clinical medical degree from Imperial College London, where she won the Norman C Lake prize for Surgery. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Tom is a Senior Operations Analyst at RA Capital Management. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . Directed by David Lowery ("The Green Knight") and featuring Law as Captain Hook, the live-action remake leans into the bittersweet coming-of-age theme of J.M. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Jake Simson is a Partner at RA Capital Management. Sarah teaches a course at Harvard Law School on venture capital fund formation. Phi previously worked as an Executive Assistant at Relay Therapeutics. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities.
Aritzia Hoodie Sizing,
Does Ripple Milk Have A Seal,
Big 4 Exit Opportunities Uk,
Articles P